Abstract: The present invention relates to a method for producing metal nanoparticles and metal nanoparticles produced thereby, in particular, to a method for producing metal nanoparticles used for inkjet that comprises, preparing metal nanoparticles capped with a fatty acid; heating a mixture of the capped metal nanoparticles and a linear or branched first amine of C1-C7 so that a part of the fatty acid is substituted to the first amine; and heating after adding a linear or branched second amine of C8-C20 to the mixture so that the first amine is re-substituted to the second amine. According to the present invention, metal nanoparticles capped with 2 kinds of dispersants can be produced massively, and its application to ink for inkjet technique can lower the curing temperature of ink.

Abstract: Metal-containing complexes of a tridentate beta-ketoiminate, one embodiment of which is represented by the structure: wherein M is a metal such as calcium, strontium, barium, scandium, yttrium, lanthanum, titanium, zirconium, vanadium, tungsten, manganese, cobalt, iron, nickel, ruthenium, zinc, copper, palladium, platinum, iridium, rhenium, osmium; R1 is selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, and aryl, having 1 to 10 carbon atoms; R2 is selected from the group consisting of hydrogen, alkyl, alkoxy, cycloaliphatic, and aryl; R3 is linear or branched selected from the group consisting of alkylene, fluoroalkyl, cycloaliphatic, and aryl; R4 is a branched alkylene bridge with at least one chiral center; R5-6 are individually linear or branched selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, aryl, and can be connected to form a ring containing carbon, oxygen, or nitrogen atoms; n is an integer equal to the valence of the metal M.

Abstract: The present invention relates to a ruthenium complex, represented by the following formula (I): RuLL?X2??(I) wherein L, L? and X are defined the same as the specification. The ruthenium complex of the present invention is suitable for Dye-Sensitized Solar Cell (DSSC) and has good photoelectric characteristics.

Abstract: The present invention provides a reusable transition metal complex catalyst useful for the preparation of high pure quality 3,3?-diaminobenzidine and its analogues. The present invention also provides to a process for the preparation of a reusable transition metal complex catalyst. The present invention further provides a process for the preparation of 3,3?-diaminobenzidine (DAB) or 3,3?,4,4? Tetraminobiphenyl (TAB) using reusable transition metal complex catalyst. The high quality 3,3?-diaminobenzedine (DAB) and its analogues are prepared by coupling 4-halo-2-nitroaniline to 3,3?-dinitrobenzidine (DNB) using transition metals as catalysts followed by reduction of 3,3?-dinitrobenzidine to the corresponding substituted 3,3?-diaminobenzidine of formula 1 in high yields.

Abstract: The present invention describes novel organometallic compounds which are phosphorescence emitters. Such compounds can be used as active components (=functional materials) in a series of different types of application which can be classed within the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (I), (Ia), (II) and (IIa).

Abstract: The present application describes deuterium-enriched oxaliplatin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: The present invention provides an asymmetric reduction catalyst effective in preparing optically-active alcohol compounds having various functional groups, and a process for preparing optically-active alcohol compounds using said asymmetric reduction catalyst. The organic metal compound of the present invention is represented by the following general formula (1): wherein R1 and R2 may be mutually identical or different, and are an alkyl group, a phenyl group, a naphthyl group, a cycloalkyl group, or an alicyclic ring formed by binding R1 and R2, which may have a substituent; R3 is a hydrogen atom or an alkyl group; Cp is a cyclopentadienyl group, which may have a substituent, bound to M1 via a ? bond; X1 is a halogen atom or a hydrido group; M1 is rhodium or iridium; and * denotes asymmetric carbon.

Abstract: The present disclosure provides a polymerizable compound of the formula (I) where the R1, R2, R?1, R?2, X1 to X8, Y1, Y2, M and L have any of values as defined in the specification. The disclosure also provides an oligomer, a homo-polymer, or a co-polymer of compound of the formula (I). The disclosure also provides methods for preparing the compound of the formula (I) and methods for preparing polymers of the compound of the formula (I), and to methods and intermediates useful for preparing them. The disclosure also provides methods for the use of the polymers of formula (I) as chiral catalysts in enantioselective preparative processes.

Abstract: Functional linkers or anchors interconnecting graphene-like carbon, such as nanotubes or graphite sheets, with a conducting material such as a metal, are shown, together with related structures, devices, methods and systems.

Abstract: The present invention relates to an improved process for the preparation of oxaliplatin, the obtained oxaliplatin preparation and its use in cancer therapy.

Abstract: The invention relates to a process for the manufacture of a compound of formula: (Formula I); or a salt, especially a pharmaceutically acceptable salt with a base, thereof or a lactone thereof wherein the element (a) represents —CH2—CH2 CH— or —CH?CH— and R represents a cyclic radical.

Abstract: A process for the preparation of a compound of Formula (1): wherein: X is S, O or NR3, wherein R3 is H or an organic group; R is H or an organic group; R1 and R2 each independently are H, optionally substituted alkyl or optionally substituted aryl; G is a substituent; and n is 0 to 3: which comprises the steps: (a) reacting a compound of Formula (2) with a compound of Formula NHR1R2 to give a compound of Formula (3): wherein X, R, G and n are as defined above and R4 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl or a combination thereof; and (b) reducing the compound of Formula (3) to give a compound of Formula (1) is provided.

Abstract: The present invention is directed to provide a catalyst for reduction, which is capable of reducing even mono-substituted alkynes to alkenes and does not require the coexistence (combined use) of a toxic compound, and a method for reduction from alkynes to alkenes using the catalyst; and relates to a palladium-supported polyethyleneimine compound obtained by contacting a polyethyleneimine, a palladium compound and hydrogen gas in an oxygen-free state, a method for producing the above palladium-supported polethyleneimine compound, a catalyst for reduction comprising the above palladium-supported polyethyleneimine compound, and a method for reducing from alkynes to alkenes characterized by contacting an alkyne and hydrogen in the presence of a palladium-supported polyethyleneimine compound, which is obtained by reacting a polyethyleneimine, a palladium compound and hydrogen gas in an oxygen-tree state.

Abstract: The invention relates to an enantiomerically enriched chiral compound comprising a transition metal M, which comprises four, five or six coordinating groups of which at least one pair is linked together to form a bidentate ligand, in which M is directly bound via one single ?-bond to a carbon atom of an optionally substituted and/or optionally fused (hetero)aromatic ring of said bidentate ligand and in which M is directly bound to a nitrogen atom of a primary or secondary amino group of said bidentate ligand, thereby forming a metallacycle between said bidentate ligand and the metal M, said metal M being selected from the metals of groups 8 and 9 of the Periodic Table of the Elements, in particular iron, ruthenium, osmium, cobalt, rhodium, or iridium. The chiral compound can be used as a catalyst, preferably in an asymmetric transfer hydrogenation process.

Abstract: Embodiments in accordance with the present invention provide for a palladium complex characterized by the general formula: where A is a bidentate monoanionic ligand, NHC is a nucleophilic heterocyclic carbene, and Z is an anionic ligand. Such palladium complexes are useful in initiating cross-coupling reactions.

Abstract: A sulfonate catalyst represented by the formula below and a ketone compound are placed in a solvent, and the ketone compound is hydrogenated by mixing in the presence of hydrogen to produce an optically active alcohol.

Abstract: We disclose here processes for making Platinum complex of general formula (I) where in, the conformation of 1,2-diaminocyclohexane is cis, trans-l or trans-d isomer and R1 and R2 combinedly make dicarboxylic acid having formulae (II), (III) and (IV), here in, the two carboxylic acid groups are on the same or on vicinal carbon atoms, n is zero or an integer ranging from 1 to 5 and R3 is either hydrogen or a substituent with electron withdrawing or electron releasing effects exemplified by alkoxy, halo, and nitro groups by reacting a compound of formula M2PtX4 wherein X represents halogen atom such as Cl or Br or thiocyanate with (i) 1,2-diaminocyclohexane (ii) source of silver ion selected from a silver compound containing divalent anion in presence of a corresponding carboxylic acid of formula (II) or (III) or (IV) to get the compound of formula (I), purifying the said compound by treating with alkali metal iodide and isolating the title compound by any conventional methods.

Abstract: A white or whitish luminescent material for phosphorescence is provided by synthesizing an organometallic complex that is able to convert a triplet excited state into light emission. In particular, a white electroluminescent device that has a high luminous efficiency and can be manufactured easily is provided by using the organometallic complex to manufacture a white or whitish electroluminescent device. The electroluminescent device is used to provide a light-emitting device with low power consumption. A fluorescent and phosphorescent material represented by a general formula (2) is synthesized.

Abstract: Disclosed herein are novel platinum-based analogs possessing two nitrile substituent groups (bis-nitrile) covalently-bonded to the platinum. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as quantitative in vitro IC50 data.

Abstract: The invention provides generally a new type of organic electrochromic Near Infrared (NIR)-active materials capable of absorbing and attenuating the light in the NIR region around 1550 nm and forming thin films on electrodes for variable optical attenuator (VOA) applications. They have utility in planar VOA devices. The materials are ruthenium complexes. Unsymmetrical complexes having two different substituents are disclosed, where one substituent is more electron-donating than the other. Complexes which are dimers or trimers (symmetrical or unsymmetrical) are disclosed, as are polymeric complexes. Crosslinked polymeric complex films are also disclosed.

Abstract: This invention relates to a catalyst compound represented by the formula: wherein: M is a Group 3 to 12 transition metal; each Ra is, independently, a hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group or halogen; each of R1, R2, R3, R4, R5, R7, R8, R9, R10, and R11 is, independently a hydrogen, a hydrocarbyl group, a substituted hydrocarbyl group or halogen; R6 is hydrogen, a hydrocarbyl group, or a substituted hydrocarbyl group; x is 0, 1, 2, 3 or 4; and each Z is, independently, a group 15 atom. This invention also relates to catalyst systems comprising the above catalyst compound and a activator and the use of such catalyst systems to polymerize monomers, including olefin monomers.

Abstract: A process for forming a tris-cyclometallated complex comprises the step of reacting; a) an M(I) complex, wherein M represents Rh or Ir, and said complex comprises at least two ligands and contains at least two alkenyl groups pi-bonded to M, with b) a heterocyclic compound capable of forming a organometallic cyclometallated complex.

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NNO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: This invention provides a method for producing an optically active aziridine compound or amine compound, which uses as a catalyst a Ru(salen)(CO) complex represented by the following formula (I) or its enantiomer having a high stability, in a high turnover number (TON) and a high enantioselectivity. In the formula (I), Ar is represented by the following formula (VI) or (VII), wherein in the formula (VI), Xs are independently a halogen or a halogenated alkyl group and R1 and R2s are independently hydrogen or an alkyl group or a trialkylsilyl group having a carbon number of 1-4, and in the formula (VII), R3 is a bulky group.

Abstract: Oxaliplatin with a low content of accompanying impurities originating from its preparation which contains, by weight, at most 0.01%, preferably less than 0.001%, of alkali metals, at most 0.0005%, preferably less than 0.0002%, of silver, and at most 0.01%, preferably less than 0.001%, of nitrates. A method for preparation of the said oxaliplatin resides in that a suspension of (SP-4-2)-dichloro-[(1R,2R)-1,2-cyclohexanediamine-N,N?]platinum(II) in water is treated with silver nitrate, then, after removal of the solid phase, the obtained solution is treated with quaternary ammonium iodide of the formula (R)4NI, the separated solid phase is removed and the obtained solution is treated with oxalic acid, and the separated oxaliplatin is isolated, washed with water and a polar organic solvent or their mixture, dried, recrystallised from water, washed with water and polar organic solvent or their mixture, and dried.

Abstract: A platinum complex represented by the general formula (1) below, useful as a phosphorescence emission material, a tetradentate ligand useful for synthesizing the platinum complex, and a light-emitting device containing at least one of the platinum complex. wherein ring B represents a nitrogen-containing aromatic heterocyclic ring; rings A, C and D each independently represent an aromatic or aromatic heterocyclic ring, while either of the rings C and D represents five-membered ring, the other represents a five- or six-membered ring; RA, RB, RC, and RD respectively represent substituents on the rings A, B, C, and D; two of XA, XB, XC, and XD represent a nitrogen atom that may be bound with the platinum atom by a coordinate bond, the others each independently represent a carbon atom or nitrogen atom that may be bound with the platinum atom by a covalent bond; Q represents a bivalent atom or atomic group bridging the rings B and C; and YC and YD each independently represent a carbon atom or nitrogen atom.

Abstract: Methods and compositions for the generation of polypeptides having varied material properties are disclosed herein. Methods include means for initiating the polymerization of aminoacid-N-carboxyanhydride (NCA) monomer by combining the monomer with an amido-containing metallacycle, for making self assembling amphiphilic block copolypeptides and related protocols for adding oligo(ethyleneglycol) functionalized aminoacid-N-carboxyanhydrides (NCAs) to polyaminoacid chains. Additional methods include means of adding an end group to the carboxy terminus of a polyaminoacid chain by reacting an alloc-protected amino acid amide with a transition metal-donor ligand complex to forming an amido-amidate metallacycle for use in further polymerization reactions. Novel compositions for use in peptide synthesis and design including five and six membered amido-containing metallacycles and block copolypeptides are also disclosed.

Abstract: A process for the preparation of diaminocyclohexane-platinum(II)-dicarboxylates has the following steps: B Conversion of K2PtX2 with 1,2-diaminocyclohexane (DACH) to (2): C Conversion of (2) with too little quantity of silver salt AgnA to (3): and removal of the resulting AgX precipitate. D Conversion of (3) with a dicarboxylate to (1): F Isolation of the product (1), wherein R1 and R2 together form a dicarboxylato group, X stands for Cl or I, A for a 1-2-valent anion of a mineral acid, and n stands for 1 or 2.

Abstract: An organometallic complex which includes a carboxylic acid as an ancillary ligand, and an organic electroluminescent device employing the same. The organometallic complex is useful as a phosphorescence dopant material of an organic electroluminescent device due to its high luminosity in the range of the blue wavelengths.

Abstract: The invention provides a method for producing an iridium complex with a high yield at a low temperature, and an organic electroluminescence device (organic EL device) having an light output high in efficiency and high luminance in a range from blue to red region. An iridium complex for the organic EL device is produced from an iridium complex having a 4-membered ring structure as an auxiliary ligand.

Abstract: Multinuclear platinum compounds, compositions that include the platinum compounds, methods for making the platinum compounds, and methods for treating cellular proliferative diseases by administering the platinum compounds.

Abstract: Disclosed herein are novel platinum-based analogs with a single substituted imine ligand: R7RC?NR8, wherein the R7RC?NR8 functional group is covalently bonded to the platinum through nitrogen. The analogs also have nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA, and one or more leaving groups which can be displaced by water, hydroxide ions or other nucleophiles, which is thought to form active species in vivo, and then, form cross-linked complexes between nucleic acid strands, principally between purines in DNA (or RNA), i.e., at the Guanine or Adenine bases, thereof.

Abstract: The present invention relates to a novel class of supermolecular carboplatin derivatives represented by general formula (I), wherein B is a polycarboxylic acid represented by general formula (II), wherein R1, R2 and n are defined as in the description. The present invention also relates to a process for preparing the same, pharmaceutical compositions containing the same as active ingredient and the use of the derivatives in the preparation of pharmaceutical compositions which are useful in treating various cellular cancers including hepatoma, stomach cancer, lung cancer and the like. The derivatives have stable cage-like chemical structures and constitutions in solid and in aqueous solution.

Abstract: A catalytic transfer hydrogenation process is provided. The catalyst employed in the process is a metal hydrocarbyl complex which is coordinated to defined bidentate ligands substituted with at least one group selected from an optionally substituted sulphonated hydrocarbyl group, a sulphonated perhalogenated hydrocarbyl group, or an optionally substituted sulphonated heterocyclyl group. Preferred metals include rhodium, ruthenium and iridium. Preferred bidentate ligands are diamines and aminoalcohols, particularly those comprising chiral centres. The hydrogen donor is advantageously a secondary alcohol or a mixture of triethylamine and formic acid. The process can be employed to transfer hydrogenate ketones and imines, which are preferably prochiral. Catalysts for use in such a process are also provided.

Abstract: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancer

Abstract: The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes.

Abstract: Disclosed herein are novel platinum-based complexes possessing one nitrile substituent group (mononitrile) covalently-bonded to the platinum, one or more nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA and leaving groups (i.e., L1 and L2) which can be hydrolyzed in vivo to active species, which can then form coordinate adducts with DNA or RNA at the Guanine or Adenine bases thereof. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as methods of treatment of various types of cancer by the administration of a pharmaceutically-effective dose of said novel platinum complexes.

Abstract: Platinum containing compounds exhibiting cytostatic activity, methods of synthesizing platinum-containing compounds exhibiting cytostatic activity pharmaceutical compositions comprising platinum containing compounds, and methods of using such compounds and compositions for treating cancer are disclosed.

Abstract: The present invention is related to pure cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex, and a process of its preparation. The present invention is further related to the preparation of oxaliplatin using said cis-diiodo-(trans-L-1,2-cyclohexanediamine) Pt (II) complex.

Abstract: Metal ketoiminate or diiminate complexes, containing copper, silver, gold, cobalt, ruthenium, rhodium, platinum, palladium, nickel, osmium, or indium, and methods for making and using same are described herein. In certain embodiments, the metal complexes described herein may be used as precursors to deposit metal and metal-containing films on a substrate through, for example, atomic layer deposition or chemical vapor deposition conditions.

Abstract: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labil

Abstract: A class of anionic and neutral complexes of ruthenium (II) containing nitrogen oxide (NO) and optionally a nitrogen ligand is described; a process for their preparation is also described. The preparation process includes the use of starting complexes of ruthenium (III) which are reacted with suitable reagents so as to obtain complexes containing NO coordinated to ruthenium (II). Additional substitution reactions allow the introduction of new groups that coordinate to the ruthenium atom, among which some nitrogen ligands.

Abstract: The present invention relates to amidomalonate O,O?—Pt and N,O—Pt chelates and methods of preparing them in essentially pure form.

Abstract: A complex of transition metal Ti, Fe, Co, Ni, Cr, Mn, Ta, Rh, Y, Sc, Ru, Pd, Zr, Hf, V or Nb and a mono-, bi-, tri-, or tetra-dentate ligand, wherein at least one of the donor atoms of the ligand is a nitrogen atom N with a 5-membered heterocyclic substituent joined to the N by a carbon atom. The complex is preferably formula (I) wherein R5—N-G-X1 is a bi-, tri, or tetra-dentate ligand, N is joined to G by an imine linkage; G is a bridging group which can contain a third or fourth donor atom; X1 is —O or —S if the X1-M bond is covalent, or if the X1-M bond is dative X1 is ?S, —PR7R8, —PR8R9, ?NR7, ?NR8, —NR7R8 or —NR8R9; R5 and R7 are 5-membered heterocyclic substituents joined to the nitrogen (or phosphorus) atoms via a carbon atom: R8 and R9 are hydrocarbyl or heterohydrocarbyl, substituted hydrocarbyl or aryl substituent; X represents an atom or group covalently or ionically bonded to the transition metal M; L is a group datively bound to M, and n is from 0 to 5; q is 1 or 2.

Abstract: A chiral compound, particularly a chiral secondary alcohol, can be efficiently resolved under a mild condition by acylation with an alkenyl acetate in the presence of a novel aminocyclopentadienyl ruthenium complex, an enzyme catalyst, and a base.

Abstract: The invention concerns low-molecular platinum complexes containing cyclobutane-1,1-dicarboxylate ligands that contain a protein-binding group.

Abstract: The present invention is directed to novel fluorinated dye stabilizers having both high quenching efficiency and solubility in halogenated solvents. These dye stabilizers have shown a significantly effect on improving the dye fastness in hostile photooxidation conditions.

Abstract: In part, the present invention is directed to coordination complexes comprising a therapeutic agent. In one aspect, the subject compositions comprise a platinum metal center and a covalently attached therapeutic agent.

Abstract: Platinum carboxylate anticancer compounds, pharmaceutical compositions that include the platinum carboxylate compounds, and methods for treating cellular proliferative diseases by administering the platinum carboxylate compounds.

Abstract: The present invention concerns novel platinum complexes in which at least one of the amine ligand is a non-planar heterocyclic aliphatic amine. The platinum complexes may be in a trans or cis configuration and were found to posses therapeutic activites. Thus, the present concerns novel platinum complexes, pharmaceutical compositions comprising them and other uses thereof.